Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
Submitted by
admin
on October 15, 2015 - 3:54pm
Source:
Fierce Pharma
News Tags:
FDA
Boehringer Ingelheim
Pradaxa
Headline:
FDA's review of BI's Pradaxa was 'lax' and 'permissive,' watchdog claims
Do Not Allow Advertisers to Use My Personal information
